COMMUNIQUÉS West-GlobeNewswire

FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
22/12/2025
Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute Availability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval supported by data [...]
Ipsen élargit son portefeuille de produits en développement précoce avec un conjugué anticorps-médicament innovant développé par Simcere Zaiming
22/12/2025
Ipsen obtient les droits mondiaux exclusifs, en dehors de la Grande Chine, pour le développement, la fabrication et la commercialisation de SIM0613, un conjugué anticorps-médicament ciblant le récepteur LRRC15. SIM0613 [...]
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
22/12/2025
Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate SIM0613 is optimally designed for superior tumor [...]
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
22/12/2025
Introduction of AVT05 supported by NHS England tender award in the United Kingdom REYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the [...]
SAFE, PARRAIN DE LA XIIème CONFERENCE INTERNATIONALE MAMMI EN ITALIE
22/12/2025
SAFE, PARRAIN DE LA XII ème CONFERENCE INTERNATIONALE MAMMI EN ITALIE Présentation de sa technologie Sycamore lors d'une intervention chirurgicale en direct Fleurieux-sur-l’Arbresle – France – 22 décembre 2025 – 8h - [...]
SAFE, SPONSOR OF THE 12TH MAMMI INTERNATIONAL CONFERENCE IN ITALY
22/12/2025
SAFE, SPONSOR OF THE 12TH MAMMI INTERNATIONAL CONFERENCE IN ITALY Presentation of its Sycamore technology during a live surgical procedure Fleurieux-sur-l’Arbresle – France – December 22, 2025 – 8am - Safe (FR001400ZU25 [...]
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
22/12/2025
Introduction of AVT05 supported by NHS England tender award in the United Kingdom REYKJAVIK, ICELAND (December 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and [...]
Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13
22/12/2025
Windward Bio and Qyuns Therapeutics announce licensing agreement for WIN027, a highly potent, long-acting bispecific antibody with best-in-disease potential in respiratory and dermatology WIN027 blocks 2 well-validated [...]
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
21/12/2025
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides a precision medicine portfolio update in relation to: TLX591-CDx ( [...]
What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives
20/12/2025
Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare at $294-534 vs. $4,800-7,200 for Pharmaceutical GLP-1 LAKELAND, Dec. 20, 2025 (GLOBE NEWSWIRE [...]
The 3D-Flow Architecture Breakthrough: A Universal, Scalable Digital Processor for Real-Time Pattern Recognition in High-Rate Data Streams — A Platform to Save Millions of Lives and Billions of Euros
20/12/2025
A Revolutionary ATCA/VME/VXI 3D-Flow Board: 512 Channels, >2,800 Programmable Operations—Scalable to >50,000 Operations on Each Dataset Arriving Every 25 ns with Zero Data Loss at a fraction of the cost of FPGA [...]
Is MEDVi the Best GLP-1 Supplier for 2026? Platform Lists Compounded Semaglutide at $179/Month With No Contract Ahead of Weight Loss Season
20/12/2025
Telehealth Platform Offers Compounded GLP-1 Injections and Oral Tablets at $299/Month With No Contract as 100,000+ Patients Seek Affordable Semaglutide Access Heading Into New Year Weight Loss Season Los Angeles, Dec. [...]
Clemson University and Nordic Wellness Launch Groundbreaking Partnership to Transform the Student Mental Health Crisis
20/12/2025
Clemson University and Nordic Wellness have launched a pioneering partnership tackling the student mental health crisis through peer-led cold plunging and breathwork programs. The initiative empowers students and alumni [...]
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
19/12/2025
Reducing inflammation helps create a regenerative environment in the Central Nervous System TORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ [...]
Nyxoah Annonce L’Émission de la Première Tranche des Obligations Convertibles
19/12/2025
Nyxoah Annonce L’Émission de la Première Tranche des Obligations Convertibles Mont-Saint-Guibert, Belgique – 19 décembre 2025, 10:05p.m. CET / 4:05 p.m. ET – Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) (« Nyxoah » ou la [...]
Nyxoah Announces Issuance of First Tranche of Convertible Bonds
19/12/2025
Nyxoah Announces Issuance of First Tranche of Convertible Bonds Mont-Saint-Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ Nyxoah ” or the “ Company ”), a [...]
Lifeward Appoints Bob Marshall as Chairman of the Board
19/12/2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd ., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/12/2025
WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/12/2025
NOVATO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]

Pages